NOTCH1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

4851

Related biomarkers:

‹

NOTCH1 amplification (1)

NOTCH1 deletion (1)

NOTCH1 amplification (1)

NOTCH1 deletion (1)

›

NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
NOTCH1 mutation	Non Small Cell Lung Cancer	NOTCH1 mutation	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ibrutinib + rituximab + obinutuzumab Resistant: B - Late Trials ibrutinib + rituximab + obinutuzumab Resistant : B	ibrutinib + rituximab + obinutuzumab Resistant: B - Late Trials ibrutinib + rituximab + obinutuzumab Resistant : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: B - Late Trials venetoclax + ibrutinib Sensitive : B	venetoclax + ibrutinib Sensitive: B - Late Trials venetoclax + ibrutinib Sensitive : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
NOTCH1 mutation	Non Small Cell Lung Cancer	NOTCH1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3	prednisone Sensitive: C3 – Early Trials prednisone Sensitive : C3
NOTCH1 mutation	Prolymphocytic Leukemia	NOTCH1 mutation	Prolymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
NOTCH1 mutation	Mantle Cell Lymphoma	NOTCH1 mutation	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
NOTCH1 mutation	Diffuse Large B Cell Lymphoma	NOTCH1 mutation	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
NOTCH1 mutation	Diffuse Large B Cell Lymphoma	NOTCH1 mutation	Diffuse Large B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
NOTCH1 mutation	Colorectal Cancer	NOTCH1 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
NOTCH1 mutation	Adenoid Cystic Carcinoma	NOTCH1 mutation	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
NOTCH1 mutation	Mantle Cell Lymphoma	NOTCH1 mutation	Mantle Cell Lymphoma	Compound E Sensitive: D – Preclinical Compound E Sensitive : D	Compound E Sensitive: D – Preclinical Compound E Sensitive : D
NOTCH1 mutation	Triple Negative Breast Cancer	NOTCH1 mutation	Triple Negative Breast Cancer	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D
NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D	CB-839 Sensitive: D – Preclinical CB-839 Sensitive : D
NOTCH1 mutation	T Acute Lymphoblastic Leukemia	NOTCH1 mutation	T Acute Lymphoblastic Leukemia	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D	IACS-010759 Sensitive: D – Preclinical IACS-010759 Sensitive : D
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D

NOTCH1 mutation

Associations